Active MMP-9-Binding Peptide for Selective MMP Inhibition

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing MMP-9 inhibitors, including low molecular weight compounds and antibodies, lack specificity and often inhibit other MMPs, leading to severe side effects, while there is a need for a peptide that selectively targets active MMP-9 without affecting its inactive form.

Innovation Solution

Development of a SPINK2 mutant peptide that specifically binds to the enzyme active domain of active human MMP-9, inhibiting its activity without affecting pro-MMP-9, and can be produced through genetic engineering or chemical synthesis, with potential conjugates for enhanced functionality.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If low molecular weight compounds that chelate zinc ion are used as MMP-9 inhibitors, then potent MMP-9 inhibitory activity is achieved, but other MMPs are also strongly inhibited leading to serious side effects

Engineering Contradiction:
ImproveMMP-9 inhibitory activityVSAvoidside effects from non-selective inhibition
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention targets a specific local region (enzyme active domain) of MMP-9 with high sequence homology, using a peptide designed to recognize this particular locale. The peptide specifically binds to the enzyme active domain while avoiding binding to propeptide regions, achieving selective inhibition of active MMP-9 without affecting other MMPs or the inactive pro-MMP-9 form.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The invention changes the molecular parameters by using a peptide-based inhibitor rather than low molecular weight compounds. The peptide contains specific amino acid sequences with particular physicochemical properties that enable selective binding to the enzyme active domain, altering the inhibition mechanism from non-selective zinc chelation to selective peptide-protein interaction.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If antibodies are used to inhibit MMP-9, then MMP-9 inhibitory activity is achieved, but the molecules are large and complex

Engineering Contradiction:
ImproveMMP-9 inhibitory activityVSAvoidmolecular complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The invention extracts only the essential functional element needed for MMP-9 inhibition - a small peptide sequence that specifically binds to the enzyme active domain. This peptide represents a simplified, extracted version of the inhibitory function, eliminating the need for large antibody molecules while retaining the core inhibitory mechanism.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention employs a small, simple peptide molecule rather than a large, complex antibody. The peptide is easier to produce, modify, and administer, representing a simpler, more practical inhibitor that can be synthesized chemically or produced recombinantly without the complexities of antibody engineering.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Reliability

If a peptide is designed to bind to the enzyme active domain of active MMP-9, then specific inhibition of active MMP-9 is achieved, but the peptide must distinguish between active and inactive forms

Engineering Contradiction:
Improvespecificity for active MMP-9VSAvoiddifficulty in distinguishing active from inactive form
Core Design Contradiction:
ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The peptide is designed to target the enzyme active domain, a specific local region that exists in both active and inactive forms but has different conformational states. The peptide recognizes structural features specific to the active conformation, enabling discrimination between active and inactive MMP-9 through localized structural recognition rather than relying on overall molecular differences.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The SPINK2 mutant peptide effectively inhibits active MMP-9 activity, providing a targeted therapeutic approach for MMP-9-related diseases with reduced side effects, and enables detection and diagnosis of active MMP-9.

Implementation Method 1

a SPINK2 mutant peptide which binds to active human MMP-9 but does not bind to pro human MMP-9... binds to an enzyme active domain of the active human MMP-9

Methodology Applied
Scientific EffectMolecular recognition and binding:

Data Source

PatentEP3656861B1Active MMP9-binding peptide
Publication Date: 2025.07.23 DAIICHI SANKYO CO LTD
  • EP3656861B1 patent drawingFigure 1(A)
  • EP3656861B1 patent drawingFigure 1(B)
  • EP3656861B1 patent drawingFigure 1(C)

AI summary

The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.